CYTEK BIOSCIENCES, INC. Cost of Revenue
CYTEK BIOSCIENCES, INC. (CTKB) reported Cost of Revenue of $19.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. cost of goods and services sold for the quarter ending 2026-06-30 was $19.80M, a 8.90% decline year-over-year.
- CYTEK BIOSCIENCES, INC. cost of goods and services sold for the quarter ending 2026-03-31 was $22.88M, a 7.42% increase year-over-year.
- CYTEK BIOSCIENCES, INC. cost of goods and services sold for the quarter ending 2025-12-31 was $29.26M, a 22.80% increase year-over-year.
- CYTEK BIOSCIENCES, INC. cost of goods and services sold for the quarter ending 2025-09-30 was $24.74M, a 9.99% increase year-over-year.
- CYTEK BIOSCIENCES, INC. cost of goods and services sold for fiscal 2025 was $97.03M, a 8.60% increase from fiscal 2024.
- CYTEK BIOSCIENCES, INC. cost of goods and services sold for fiscal 2024 was $89.35M, a 6.89% increase from fiscal 2023.
- CYTEK BIOSCIENCES, INC. cost of goods and services sold for fiscal 2023 was $83.59M, a 32.55% increase from fiscal 2022.
- CYTEK BIOSCIENCES, INC. cost of goods and services sold for fiscal 2022 was $63.06M, a 29.21% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.80M 10-Q · filed 2026-08-05 | $42.68M 10-Q · filed 2026-08-05 | $71.94M derived: sum of 3 quarters · filed 2026-08-05 | $96.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $22.88M 10-Q · filed 2026-05-07 | $52.14M derived: sum of 2 quarters · filed 2026-05-07 | $76.88M derived: sum of 3 quarters · filed 2026-05-07 | $98.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $29.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $54.00M derived: sum of 2 quarters · filed 2026-02-26 | $75.73M derived: sum of 3 quarters · filed 2026-08-05 | $97.03M 10-K · filed 2026-02-26 |
| 2025-09-30 | $24.74M 10-Q · filed 2025-11-05 | $46.48M derived: sum of 2 quarters · filed 2026-08-05 | $67.78M 10-Q · filed 2025-11-05 | $91.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $21.73M 10-Q · filed 2026-08-05 | $43.03M 10-Q · filed 2026-08-05 | $66.86M derived: sum of 3 quarters · filed 2026-08-05 | $89.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $21.30M 10-Q · filed 2026-05-07 | $45.12M derived: sum of 2 quarters · filed 2026-05-07 | $67.62M derived: sum of 3 quarters · filed 2026-05-07 | $88.80M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $23.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $46.32M derived: sum of 2 quarters · filed 2026-02-26 | $67.50M derived: sum of 3 quarters · filed 2026-02-26 | $89.35M 10-K · filed 2026-02-26 |
| 2024-09-30 | $22.50M 10-Q · filed 2025-11-05 | $43.68M derived: sum of 2 quarters · filed 2025-11-05 | $65.52M 10-Q · filed 2025-11-05 | $90.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $21.18M 10-Q · filed 2025-08-06 | $43.03M 10-Q · filed 2025-08-06 | $68.21M derived: sum of 3 quarters · filed 2026-02-26 | $89.03M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $21.85M 10-Q · filed 2025-05-08 | $47.03M derived: sum of 2 quarters · filed 2026-02-26 | $67.85M derived: sum of 3 quarters · filed 2026-02-26 | $89.39M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $25.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $46.01M derived: sum of 2 quarters · filed 2026-02-26 | $67.54M derived: sum of 3 quarters · filed 2026-02-26 | $83.59M 10-K · filed 2026-02-26 |
| 2023-09-30 | $20.82M 10-Q · filed 2024-11-07 | $42.35M derived: sum of 2 quarters · filed 2024-11-07 | $58.40M 10-Q · filed 2024-11-07 | $77.36M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $21.53M 10-Q · filed 2024-08-06 | $37.58M 10-Q · filed 2024-08-06 | $56.54M derived: sum of 3 quarters · filed 2025-02-28 | $70.16M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $16.05M 10-Q · filed 2024-05-08 | $35.01M derived: sum of 2 quarters · filed 2025-02-28 | $48.63M derived: sum of 3 quarters · filed 2025-02-28 | $64.22M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $18.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $32.58M derived: sum of 2 quarters · filed 2025-02-28 | $48.17M derived: sum of 3 quarters · filed 2025-02-28 | $63.06M 10-K · filed 2025-02-28 |
| 2022-09-30 | $13.62M 10-Q · filed 2023-11-14 | $29.21M derived: sum of 2 quarters · filed 2023-11-14 | $44.10M 10-Q · filed 2023-11-14 | $59.36M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $15.60M 10-Q · filed 2023-08-08 | $30.48M 10-Q · filed 2023-08-08 | $45.74M derived: sum of 3 quarters · filed 2024-03-13 | $58.84M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $14.89M 10-Q · filed 2023-05-09 | $30.14M derived: sum of 2 quarters · filed 2024-03-13 | $43.24M derived: sum of 3 quarters · filed 2024-03-13 | $53.91M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $15.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $28.36M derived: sum of 2 quarters · filed 2024-03-13 | $39.02M derived: sum of 3 quarters · filed 2024-03-13 | $48.81M 10-K · filed 2024-03-13 |
| 2021-09-30 | $13.10M 10-Q · filed 2022-11-09 | $23.76M derived: sum of 2 quarters · filed 2022-11-09 | $33.55M 10-Q · filed 2022-11-09 | $44.72M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $10.66M 10-Q · filed 2022-08-10 | $20.45M 10-Q · filed 2022-08-10 | $31.62M derived: sum of 3 quarters · filed 2023-03-01 | $41.10M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $9.79M 10-Q · filed 2022-05-12 | $20.96M derived: sum of 2 quarters · filed 2023-03-01 | $30.44M derived: sum of 3 quarters · filed 2023-03-01 | $41.30M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $11.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $20.65M derived: sum of 2 quarters · filed 2023-03-01 | $31.52M derived: sum of 3 quarters · filed 2023-03-01 | $41.13M 10-K · filed 2023-03-01 |
| 2020-09-30 | $9.48M 10-Q · filed 2021-11-12 | $20.35M derived: sum of 2 quarters · filed 2021-11-12 | $29.96M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $10.87M 10-Q · filed 2021-09-03 | $20.48M 10-Q · filed 2021-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |